{
  "guideline": {
    "id": "PA166182746",
    "name": "Annotation of FDA Label for ceftriaxone and CYB5R3, G6PD",
    "source": "FDA",
    "version": 11,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166182746",
    "relatedChemicals": [
      {
        "id": "PA448866",
        "name": "ceftriaxone",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA27331",
        "name": "cytochrome b5 reductase 3",
        "symbol": "CYB5R3"
      },
      {
        "id": "PA28469",
        "name": "glucose-6-phosphate dehydrogenase",
        "symbol": "G6PD"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312418",
      "name": "Recommendation Annotation PA166312418",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA448866",
          "name": "ceftriaxone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216717,
        "html": "<p>&quot;Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, ... are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Deficient"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166315143",
      "name": "Recommendation Annotation PA166315143",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA448866",
          "name": "ceftriaxone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452245682,
        "html": "<p>&quot;Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, ... are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Variable"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312417",
      "name": "Recommendation Annotation PA166312417",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA448866",
          "name": "ceftriaxone",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216716,
        "html": "<p>&quot;Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, ... are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Deficient with CNSHA"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product ceftriaxone (NDA050585)",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=050585"
    }
  ],
  "version": "2024-02-29-20-19"
}